A Osterborg

Summary

Affiliation: Karolinska University Hospital
Country: Sweden

Publications

  1. doi request reprint Management guidelines for the use of alemtuzumab in chronic lymphocytic leukemia
    A Osterborg
    Department of Hematology, Karolinska University Hospital, Stockholm, Sweden
    Leukemia 23:1980-8. 2009
  2. doi request reprint Ofatumumab, a human anti-CD20 monoclonal antibody
    Anders Osterborg
    Department of Hematology, Karolinska University Hospital Solna, Stockholm, Sweden
    Expert Opin Biol Ther 10:439-49. 2010
  3. doi request reprint Alemtuzumab to treat refractory autoimmune hemolytic anemia or thrombocytopenia in chronic lymphocytic leukemia
    Anders Osterborg
    Department of Hematology, Karolinska University Hospital Solna, SE 171 76, Stockholm, Sweden
    Curr Hematol Malig Rep 4:47-53. 2009
  4. ncbi request reprint Phase II study of three dose levels of continuous erythropoietin receptor activator (C.E.R.A.) in anaemic patients with aggressive non-Hodgkin's lymphoma receiving combination chemotherapy
    Anders Osterborg
    Departments of Oncology and Haematology, Karolinska University Hospital, Stockholm, Sweden
    Br J Haematol 136:736-44. 2007
  5. ncbi request reprint Preclinical studies of erythropoietin receptor expression in tumour cells: impact on clinical use of erythropoietic proteins to correct cancer-related anaemia
    Anders Osterborg
    Department of Oncology, Karolinska University Hospital, SE 171 76 Stockholm, Sweden
    Eur J Cancer 43:510-9. 2007
  6. ncbi request reprint Strategies in the management of alemtuzumab-related side effects
    Anders Osterborg
    Department of Oncology and Hematology, Karolinska University Hospital, Stockholm, Sweden
    Semin Oncol 33:S29-35. 2006
  7. ncbi request reprint Variability in B-cell antigen expression: implications for the treatment of B-cell lymphomas and leukemias with monoclonal antibodies
    E D Rossmann
    Department of Oncology (Radiumhemmet, Cancer Center Karolinska, Karolinska Hospital, Stockholm, Sweden
    Hematol J 2:300-6. 2001
  8. ncbi request reprint Development of a dendritic cell-based vaccine for chronic lymphocytic leukemia
    M Palma
    Departments of Oncology and Hematology, Karolinska University Hospital, 171 76 Stockholm, Sweden
    Cancer Immunol Immunother 57:1705-10. 2008
  9. doi request reprint Generation of a dendritic cell-based vaccine in chronic lymphocytic leukaemia using CliniMACS platform for large-scale production
    L Adamson
    Immune and Gene Therapy Laboratory, Department of Oncology and Pathology, Cancer Centre Karolinska, Stockholm, Sweden
    Scand J Immunol 69:529-36. 2009
  10. ncbi request reprint T-cell-epitope mapping of the idiotypic monoclonal IgG heavy and light chains in multiple myeloma
    J Fagerberg
    Department of Oncology Radiumhemmet, Karolinska Hospital, Stockholm, Sweden
    Int J Cancer 80:671-80. 1999

Detail Information

Publications72

  1. doi request reprint Management guidelines for the use of alemtuzumab in chronic lymphocytic leukemia
    A Osterborg
    Department of Hematology, Karolinska University Hospital, Stockholm, Sweden
    Leukemia 23:1980-8. 2009
    ....
  2. doi request reprint Ofatumumab, a human anti-CD20 monoclonal antibody
    Anders Osterborg
    Department of Hematology, Karolinska University Hospital Solna, Stockholm, Sweden
    Expert Opin Biol Ther 10:439-49. 2010
    ..Since relapse of chronic lymphocytic leukemia (CLL), and refractoriness to treatment following relapse, is inevitable after initial treatment, development of novel treatment strategies is necessary...
  3. doi request reprint Alemtuzumab to treat refractory autoimmune hemolytic anemia or thrombocytopenia in chronic lymphocytic leukemia
    Anders Osterborg
    Department of Hematology, Karolinska University Hospital Solna, SE 171 76, Stockholm, Sweden
    Curr Hematol Malig Rep 4:47-53. 2009
    ..Results from a range of reports confirm the efficacy of alemtuzumab for the treatment of severe, CLL-related autoimmune cytopenias that have failed to respond to conventional therapies and may even be rituximab-refractory...
  4. ncbi request reprint Phase II study of three dose levels of continuous erythropoietin receptor activator (C.E.R.A.) in anaemic patients with aggressive non-Hodgkin's lymphoma receiving combination chemotherapy
    Anders Osterborg
    Departments of Oncology and Haematology, Karolinska University Hospital, Stockholm, Sweden
    Br J Haematol 136:736-44. 2007
    ..C.E.R.A. was generally well tolerated in all three groups. C.E.R.A. appeared to have dose-dependent clinical activity in most anaemic patients with aggressive NHL who were receiving chemotherapy...
  5. ncbi request reprint Preclinical studies of erythropoietin receptor expression in tumour cells: impact on clinical use of erythropoietic proteins to correct cancer-related anaemia
    Anders Osterborg
    Department of Oncology, Karolinska University Hospital, SE 171 76 Stockholm, Sweden
    Eur J Cancer 43:510-9. 2007
    ..Together with diverging results in the literature, these methodological limitations indicate that findings from preclinical studies must not be over-translated in terms of their clinical relevance to patients with cancer...
  6. ncbi request reprint Strategies in the management of alemtuzumab-related side effects
    Anders Osterborg
    Department of Oncology and Hematology, Karolinska University Hospital, Stockholm, Sweden
    Semin Oncol 33:S29-35. 2006
    ..The overall safety profile of alemtuzumab appears to be beneficial in relation to disease severity and prognosis in patients with fludarabine-refractory B-cell chronic lymphocytic leukemia...
  7. ncbi request reprint Variability in B-cell antigen expression: implications for the treatment of B-cell lymphomas and leukemias with monoclonal antibodies
    E D Rossmann
    Department of Oncology (Radiumhemmet, Cancer Center Karolinska, Karolinska Hospital, Stockholm, Sweden
    Hematol J 2:300-6. 2001
    ..Caution must be taken when interpreting in vitro results on cytokine-mediated receptor intensity up-regulation...
  8. ncbi request reprint Development of a dendritic cell-based vaccine for chronic lymphocytic leukemia
    M Palma
    Departments of Oncology and Hematology, Karolinska University Hospital, 171 76 Stockholm, Sweden
    Cancer Immunol Immunother 57:1705-10. 2008
    ..Three cohorts are accrued stepwise. Cohort I receives Apo-DC alone; Cohort II: Apo-DC+ repeated doses of low-dose GM-CSF; Cohort III: low-dose cyclophosphamide followed by Apo-DC + GM-CSF...
  9. doi request reprint Generation of a dendritic cell-based vaccine in chronic lymphocytic leukaemia using CliniMACS platform for large-scale production
    L Adamson
    Immune and Gene Therapy Laboratory, Department of Oncology and Pathology, Cancer Centre Karolinska, Stockholm, Sweden
    Scand J Immunol 69:529-36. 2009
    ....
  10. ncbi request reprint T-cell-epitope mapping of the idiotypic monoclonal IgG heavy and light chains in multiple myeloma
    J Fagerberg
    Department of Oncology Radiumhemmet, Karolinska Hospital, Stockholm, Sweden
    Int J Cancer 80:671-80. 1999
    ..Such T cells could be an important part of the specific anti-tumor immune responses induced in idiotype vaccination protocols...
  11. ncbi request reprint Blood dendritic cells from myeloma patients are not infected with Kaposi's sarcoma-associated herpesvirus (KSHV/HHV-8)
    Q Yi
    Immunological Research Laboratory, Karolinska Hospital, Stockholm, Sweden
    Blood 92:402-4. 1998
    ..This study also suggests that KSHV/HHV-8 is not regularly associated with MM and consequently does not play a primary role in the pathogenesis of these tumors...
  12. ncbi request reprint Therapy of colorectal carcinoma with monoclonal antibodies (MAb17-1A) alone and in combination with granulocyte monocyte-colony stimulating factor (GM-CSF)
    H Mellstedt
    Department of Oncology, Karolinska Hospital, Stockholm, Sweden
    Acta Oncol 30:923-31. 1991
    ..The combination of MAb17-1A + GM-CSF augmented the ADCC activity of blood mononuclear cells and a heavy infiltration of monocytes could be noted in the tumor. Out of 15 available patients 6 (40%) showed a response...
  13. ncbi request reprint Dendritic cells in patients with non-progressive B-chronic lymphocytic leukaemia have a normal functional capability but abnormal cytokine pattern
    M R Rezvany
    Immune and Gene Therapy Laboratory CCK, Karolinska Hospital, Stockholm, Sweden
    Br J Haematol 115:263-71. 2001
    ..The mechanisms behind the observed increase in some surface molecules and the abnormal cytokine profile of CLL DC is not clear but might indicate pre-activation of DC in vivo, which may have a regulatory role in the pathobiology of CLL...
  14. ncbi request reprint Generation of DC-based vaccine for therapy of B-CLL patients. Comparison of two methods for enriching monocytic precursors
    P Kokhaei
    Immune and Gene Therapy Lab, CCK, Department of Oncology Pathology, Karolinska Institutet, Stockholm, Sweden
    Cytotherapy 8:318-26. 2006
    ....
  15. ncbi request reprint Phase II multicenter study of human CD52 antibody in previously treated chronic lymphocytic leukemia. European Study Group of CAMPATH-1H Treatment in Chronic Lymphocytic Leukemia
    A Osterborg
    Department of Oncology Radiumhemmet, Karolinska Hospital, Stockholm, Sweden
    J Clin Oncol 15:1567-74. 1997
    ..We report the results of a multicenter phase II trial that used CAMPATH-1H in previously chemotherapy-treated patients with chronic lymphocytic leukemia (CLL)...
  16. ncbi request reprint Idiotype immunity (natural and vaccine-induced) in early stage multiple myeloma
    A Osterborg
    Department of Oncology, Radiumhemmet and Cancer Center Karolinska, Karolinska Hospital, Stockholm, Sweden
    Acta Oncol 39:797-800. 2000
    ..The use of GM-CSF seems to be mandatory for the frequency and magnitude of the induced T-cell response. The optimal route, schedule and cytokine combination for idiotype immunization remains to be established...
  17. ncbi request reprint Oral versus intravenous melphalan and prednisone treatment in multiple myeloma stage II. A randomized study from the Myeloma Group of Central Sweden
    A Osterborg
    Department of Oncology, Karolinska Hopital, Stockholm, Sweden
    Acta Oncol 29:727-31. 1990
    ..Since intravenous administration of melphalan did not result in a substantial increase in response rate or survival, this study supports the use of oral melphalan/prednisone as first-line therapy for patients with multiple myeloma...
  18. ncbi request reprint Augmentation of the immune response with granulocyte-macrophage colony-stimulating factor and other hematopoietic growth factors
    H Mellstedt
    Department of Oncology Radiumhemmet, Karolinska Hospital, Stockholm, Sweden
    Curr Opin Hematol 6:169-75. 1999
    ..It is urgently warranted to better understand these dual effects on the immune system so that we can find optimal uses for the growth factors in various clinical settings...
  19. ncbi request reprint Apoptotic tumor cells are superior to tumor cell lysate, and tumor cell RNA in induction of autologous T cell response in B-CLL
    P Kokhaei
    Immune and Gene Therapy Lab, CCK, Karolinska Hospital, Stockholm, Sweden
    Leukemia 18:1810-5. 2004
    ..Our data suggest that cellular vaccines with DC loaded with apoptotic bodies may be a suitable approach for immunotherapy of B-CLL...
  20. ncbi request reprint The biology and treatment of chronic lymphocytic leukemia
    M Palma
    Department of Hematology, Cancer Centre Karolinska, Karolinska University Hospital, Stockholm, Sweden
    Ann Oncol 17:x144-54. 2006
  21. ncbi request reprint Predominant T cell receptor V gene usage in patients with abnormal clones of B cells
    C H Janson
    Department of Immunology, Karolinska Institute, Stockholm, Sweden
    Blood 77:1776-80. 1991
    ..T- and B-cell populations are normally clonally linked in regulatory circuits. An abnormal proliferation of B cells might therefore induce, or be regulated by, an expansion of clonal T cells, as suggested by the present results...
  22. ncbi request reprint The influence of interferon-alpha on the pharmacokinetics of cyclophosphamide and its 4-hydroxy metabolite in patients with multiple myeloma
    M Hassan
    Karolinska Pharmacy, Stockholm, Sweden
    Eur J Haematol 63:163-70. 1999
    ....
  23. doi request reprint Idiotype vaccination in patients with myeloma reduced circulating myeloma cells (CMC)
    A O Abdalla
    Immune and Gene Therapy Laboratory, Cancer Centre Karolinska, Stockholm, Sweden
    Ann Oncol 19:1172-9. 2008
    ..Circulating myeloma cells (CMC), exhibiting the same immunoglobulin heavy-chain gene rearrangements as the plasma cells, are part of the myeloma clone. In this study, we evaluated the effect of idiotype (Id) vaccination on CMC...
  24. pmc Upregulation of bfl-1 is a potential mechanism of chemoresistance in B-cell chronic lymphocytic leukaemia
    A Olsson
    Department of Tumor and Cell Biology, Karolinska Institutet, Stockholm, Sweden
    Br J Cancer 97:769-77. 2007
    ..Specific downregulation of bfl-1 using siRNA induced apoptosis in resistant cells. Our data suggest that bfl-1 contributes to chemoresistance and might be a therapeutic target in B-CLL...
  25. ncbi request reprint EORTC guidelines for the use of erythropoietic proteins in anaemic patients with cancer: 2006 update
    C Bokemeyer
    Universitaetsklinikum Hamburg Eppendorf, Martinistrasse 52, 20246 Hamburg, Germany, and Department of Haematology, Karolinska University Hospital, Stockholm, Sweden
    Eur J Cancer 43:258-70. 2007
    ..While our review did not address cost benefit evaluations in detail, the consensus is that studies taking into account all real determinants of cost and benefit need to be performed prospectively...
  26. pmc NK-cell and T-cell functions in patients with breast cancer: effects of surgery and adjuvant chemo- and radiotherapy
    F Mozaffari
    Immune and Gene Therapy Laboratory, Cancer Centre Karolinska, Karolinska University Hospital, SE 17176 Stockholm, Sweden
    Br J Cancer 97:105-11. 2007
    ....
  27. ncbi request reprint Interleukin 6, tumour necrosis factor alpha, interleukin 1beta and interleukin 1 receptor antagonist promoter or coding gene polymorphisms in multiple myeloma
    C Zheng
    Division of Haematology, and Immunological Research Laboratory, Centre for Molecular Medicine, Karolinska Hospital, Stockholm, Sweden
    Br J Haematol 109:39-45. 2000
    ..Our results indicate that the cytokine (IL-6, TNF-alpha and IL-1beta) and IL-Ra gene polymorphisms do not confer susceptibility to the development of MM...
  28. ncbi request reprint Cellular immune reconstitution after subcutaneous alemtuzumab (anti-CD52 monoclonal antibody, CAMPATH-1H) treatment as first-line therapy for B-cell chronic lymphocytic leukaemia
    J Lundin
    1Department of Haematology, Karolinska Hospital, Stockholm, Sweden
    Leukemia 18:484-90. 2004
    ..These subpopulations declined gradually during unmaintained follow-up. The relationship between these observations and the safety/antitumour effects of alemtuzumab is discussed...
  29. ncbi request reprint Sensitization to TRAIL-induced apoptosis and modulation of FLICE-inhibitory protein in B chronic lymphocytic leukemia by actinomycin D
    A Olsson
    Microbiology and Tumor Biology Center, Karolinska Institutet, Stockholm, Sweden
    Leukemia 15:1868-77. 2001
    ..In addition, neither decoy receptors nor Bcl-2 expression were affected by Act D. Our findings suggest the possible involvement of FLIP in regulating TRAIL-mediated apoptosis in B-CLL...
  30. ncbi request reprint Treatment of anemia in myelodysplastic syndromes with granulocyte colony-stimulating factor plus erythropoietin: results from a randomized phase II study and long-term follow-up of 71 patients
    E Hellstrom-Lindberg
    Department of Hematology, Huddinge University Hospital, Huddinge, Sweden
    Blood 92:68-75. 1998
    ..The international prognostic scoring system (IPSS) was effective to predict survival, leukemic transformation, and to a lesser extent, duration of response, but had no impact on primary response rates...
  31. doi request reprint Monoclonal antibodies against ROR1 induce apoptosis of chronic lymphocytic leukemia (CLL) cells
    A H Daneshmanesh
    Immune and Gene Therapy Lab, CCK, Karolinska University Hospital Solna, Karolinska Institutet, Stockholm, Sweden
    Leukemia 26:1348-55. 2012
    ..The identified ROR1 epitopes may provide a basis for generating human ROR1 MAbs for therapy...
  32. ncbi request reprint Biopsy-verified response of severe lupus nephritis to treatment with rituximab (anti-CD20 monoclonal antibody) plus cyclophosphamide after biopsy-documented failure to respond to cyclophosphamide alone
    R F van Vollenhoven
    Department of Rheumatology, Karolinska Hospital, Stockholm, Sweden
    Scand J Rheumatol 33:423-7. 2004
    ..The monoclonal anti-B cell antibody rituximab (Rituxin, Mabthera) may be of benefit in antibody-driven diseases, including systemic lupus erythematosus (SLE) nephritis...
  33. ncbi request reprint Performance of calibration standards for antigen quantitation with flow cytometry in chronic lymphocytic leukemia
    Eva D Rossmann
    Department of Oncology Radiumhemmet, Karolinska University Hospital, Stockholm, Sweden
    Cytometry B Clin Cytom 72:450-7. 2007
    ..The fluorescence intensities of CD3, CD4 on T cells and CD20, CD22 molecules on B cells were quantitatively measured on lymphocytes from chronic lymphocytic leukemia (CLL) patients and healthy donors...
  34. ncbi request reprint Reconstitution of the T-cell repertoire following treatment with alemtuzumab (anti-CD52 monoclonal antibody) in patients with B-cell chronic lymphocytic leukaemia
    Mohammad Reza Rezvany
    Immune and Gene Therapy Laboratory, Department of Oncology and Pathology, Cancer Centre Karolinska CCK, Karolinska Institutet, Stockholm, Sweden
    Br J Haematol 135:475-85. 2006
    ..These results indicate that perturbations in the T-cell alterations following alemtuzumab are complex and include not only changes in CD4/CD8 T-cell numbers but also a highly restricted T-cell repertoire especially in CD4 T cells...
  35. ncbi request reprint Phase 2 study of alemtuzumab (anti-CD52 monoclonal antibody) in patients with advanced mycosis fungoides/Sezary syndrome
    Jeanette Lundin
    Department of Hematology Oncology, Karolinska Hospital, Stockholm, Sweden
    Blood 101:4267-72. 2003
    ..Alemtuzumab shows promising clinical activity and an acceptable safety profile in patients with advanced MF/SS, particularly in patients with erythroderma and severe itching and those who were not heavily pretreated...
  36. doi request reprint Ror1, a cell surface receptor tyrosine kinase is expressed in chronic lymphocytic leukemia and may serve as a putative target for therapy
    Amir H Daneshmanesh
    Immune and Gene Therapy Lab, CCK, Karolinska Institutet and Karolinska University Hospital Solna, Stockholm, Sweden
    Int J Cancer 123:1190-5. 2008
    ..The Ror1 protein expression in patients with CLL but not in normal leukocytes merits further studies of its role in the pathobiology of CLL, which may provide a basis for development of Ror1 directed targeted therapy...
  37. doi request reprint Erythropoietins should be used according to guidelines
    Matti S Aapro
    Lancet Oncol 9:412-3. 2008
  38. ncbi request reprint Advances in the use of monoclonal antibodies in the therapy of chronic lymphocytic leukemia
    Jeanette Lundin
    Departments of Hematology Oncology, Karolinska University Hospital, Stockholm, Sweden
    Semin Hematol 41:234-45. 2004
    ..The availability of an increasing number of new moAbs together with a better understanding of their effector function will hopefully lead to improved therapeutic outcomes for patients with CLL and related disorders...
  39. ncbi request reprint Signalling molecules and cytokine production in T cells of multiple myeloma-increased abnormalities with advancing stage
    Fariba Mozaffari
    Immune and Gene Therapy Laboratory, Cancer Centre Karolinska, Karolinska Hospital, SE 171 76 Stockholm, Sweden
    Br J Haematol 124:315-24. 2004
    ..These data should be taken into consideration when developing immune-based therapeutic approaches and when applying new emerging technologies that aim to restore T-cell functions...
  40. ncbi request reprint Clinical effects of alemtuzumab (Campath-1H) in B-cell chronic lymphocytic leukemia
    Anders Osterborg
    Karolinska Hospital, Department of Hematology and Oncology, Stockholm, Sweden
    Med Oncol 19:S21-6. 2002
    ..Alemtuzumab treatment has also allowed patients with advanced disease to proceed to stem cell transplantation, and preliminary data indicate that alemtuzumab is highly effective in previously untreated patients with B-CLL...
  41. ncbi request reprint Erythropoietin therapy and cancer related anaemia: updated Swedish recommendations
    Jane Ahlqvist-Rastad
    Medical Products Agency, Uppsala 751 03, Sweden
    Med Oncol 24:267-72. 2007
    ..Until further notice it is therefore recommended that EPO should be used restrictively in the treatment of patients with cancer and that the anticipated improvement in quality of life should be evaluated against potential risks...
  42. ncbi request reprint Expression of erythropoietin receptor and in vitro functional effects of epoetins in B-cell malignancies
    Parviz Kokhaei
    Department of Oncology, Karolinska Institutet, Stockholm, Sweden
    Clin Cancer Res 13:3536-44. 2007
    ..This report describes genomic/protein EPO-R expression and in vitro effects of recombinant human EPO (epoetin) in B-cell chronic lymphocytic leukemia (B-CLL), mantle-cell lymphoma (MCL), and multiple myeloma (MM)...
  43. ncbi request reprint Signaling molecules and cytokine production in T cells of patients with B-cell chronic lymphocytic leukemia: long-term effects of fludarabine and alemtuzumab treatment
    Shahryar Kiaii
    Immune and Gene Therapy Laboratory, Cancer Center Karolinska, Stockholm, Sweden
    Leuk Lymphoma 47:1229-38. 2006
    ..The results suggest that, despite some alterations in signaling molecules and a reduction in T-cell number, overall T-cell functions may be relatively well preserved long-term after treatment with fludarabine and alemtuzumab...
  44. ncbi request reprint Phase II trial of subcutaneous anti-CD52 monoclonal antibody alemtuzumab (Campath-1H) as first-line treatment for patients with B-cell chronic lymphocytic leukemia (B-CLL)
    Jeanette Lundin
    Department of Hematology, Karolinska Hospital, and Huddinge University Hospital, Stockholm, Sweden
    Blood 100:768-73. 2002
    ..Prolonged treatment is important for maximal bone marrow response. Subcutaneous administration induced very few "first-dose" flulike symptoms and may reduce health care costs in comparison with the intravenous infusions...
  45. ncbi request reprint CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group
    Michael Pfreundschuh
    University Clinic of Saarland, Homburg, Germany
    Lancet Oncol 7:379-91. 2006
    ..We aimed to compare CHOP-like chemotherapy and rituximab with CHOP-like chemotherapy alone in these patients...
  46. ncbi request reprint Management guidelines for use of alemtuzumab in B-cell chronic lymphocytic leukemia
    Michael Keating
    M D Anderson Cancer Center, Houston, TX 77030, USA
    Clin Lymphoma 4:220-7. 2004
    ..Because high response rates and few complications are observed in previously untreated patients, the use of alemtuzumab earlier in therapy may provide optimum benefit to patients...
  47. ncbi request reprint New erythropoietic proteins: rationale and clinical data
    Anders Osterborg
    Department of Oncology, Karolinska Institute and Hospital, Stockholm, Sweden
    Semin Oncol 31:12-8. 2004
    ..This review focuses on the available clinical experience with such agents and discusses how dose- and schedule-finding studies are optimizing their clinical use to maximize patient benefits...
  48. doi request reprint Long-term molecular remissions in patients with indolent lymphoma treated with rituximab as a single agent or in combination with interferon alpha-2a: a randomized phase II study from the Nordic Lymphoma Group
    Eva Kimby
    Karolinska University Hospital, Stockholm, Sweden
    Leuk Lymphoma 49:102-12. 2008
    ....
  49. ncbi request reprint Relationship between changes in hemoglobin level and quality of life during chemotherapy in anemic cancer patients receiving epoetin alfa therapy
    Anders Osterborg
    Cancer 97:3125-6; author reply 3126-7. 2003
  50. ncbi request reprint Signaling molecules and cytokine production in T cells of patients with B-cell chronic lymphocytic leukemia (B-CLL): comparison of indolent and progressive disease
    Shahryar Kiaii
    Cancer Center Karolinska, Karolinska University Hospital, Stockholm, Sweden
    Med Oncol 22:291-302. 2005
    ..This information might be of significance when studying the immunobiology of B-CLL as well as developing new therapeutic approaches...
  51. ncbi request reprint Anemia in multiple myeloma
    Heinz Ludwig
    Department of Medicine I, Wilhelminenspital, Vienna, Austria
    Clin Adv Hematol Oncol 2:233-41. 2004
    ..Recently, an international expert panel recommended the use of rHuEPO for anemic myeloma patients where other possible causes of anemia have been eliminated...
  52. ncbi request reprint Intracellular T cell cytokines in patients with B cell chronic lymphocytic leukaemia (B-CLL)
    Eva D Rossmann
    Immune and Gene Therapy Laboratory, Cancer Center Karolinska, Karolinska Hospital, SE 171 76 Stockholm, Sweden
    Eur J Haematol 68:299-306. 2002
    ..The findings may suggest a role for T cells in the pathogenesis of B-CLL...
  53. ncbi request reprint Randomized, double-blind, placebo-controlled trial of recombinant human erythropoietin, epoetin Beta, in hematologic malignancies
    Anders Osterborg
    Department of Oncology Radiumhemmet, Karolinska Hospital, S 17176 Stockholm, Sweden
    J Clin Oncol 20:2486-94. 2002
    ....
  54. ncbi request reprint Management of disease-related anemia in patients with multiple myeloma or chronic lymphocytic leukemia: epoetin treatment recommendations
    Heinz Ludwig
    Department of Medicine and Medical Oncology, Wihelminenspital, Montleartstrasse 37, A 1171 Vienna, Austria
    Hematol J 3:121-30. 2002
    ..Epoetin treatment should be discontinued if there is no response to the increased dosage, or hemoglobin >14 g/dl. Treatment should resume for patients who exceed 14 g/dl, at a reduced dosage, if their hemoglobin falls below 12 g/dl...
  55. ncbi request reprint Phase II study of cyclophosphamide, interferon-alpha and betamethasone (CIB) as induction therapy for patients 60-75 years of age with multiple myeloma stages II and III
    Jeanette Lundin
    Department of Hematology, Karolinska Hospital, Stockholm, Sweden
    Hematol J 4:248-52. 2003
    ....
  56. ncbi request reprint Phase I study of a novel pro-apoptotic drug R-etodolac in patients with B-cell chronic lymphocytic leukemia
    Markus Jensen
    University of Cologne, Kerpener Strasse 62, 50924, Cologne, Germany
    Invest New Drugs 26:139-49. 2008
    ..Further study of R-etodolac as a possible new maintenance therapy or as a part of combination therapy of B-CLL appears warranted...
  57. ncbi request reprint Long-term effects of idiotype vaccination on the specific T-cell response in peripheral blood and bone marrow of multiple myeloma patients
    Amir Osman Abdalla
    Immune and Gene Therapy Laboratory, CCK, Karolinska University Hospital Solna, Stockholm, Sweden
    Eur J Haematol 79:371-81. 2007
    ..To elucidate long-term effects of idiotype (Id) vaccination on Id-specific T cells of multiple myeloma (MM) patients and compare Id-specific T-cell responses of peripheral blood with those of bone marrow (BM)...
  58. doi request reprint The cost-effectiveness of treatment with erythropoietin compared to red blood cell transfusions for patients with chemotherapy induced anaemia: a Markov model
    Sixten Borg
    The Swedish Institute for Health Economics IHE, Lund, Sweden
    Acta Oncol 47:1009-17. 2008
    ..It is generally accepted that symptomatic anaemia should be corrected. Treatment options include red blood cell transfusion (RBCT), erythropoietin (EPO) administration or a combination of both...
  59. ncbi request reprint Fibromodulin, an extracellular matrix protein: characterization of its unique gene and protein expression in B-cell chronic lymphocytic leukemia and mantle cell lymphoma
    Eva Mikaelsson
    Immune and Gene Therapy Laboratory, CCK, Department of Oncology, Karolinska University Hospital, Stockholm, Sweden
    Blood 105:4828-35. 2005
    ..The reason for the exclusive ectopic expression of fibromodulin in B-CLL and MCL is unknown. However, its unique protein expression makes it likely that fibromodulin is involved in the pathobiology of B-CLL and MCL...
  60. ncbi request reprint Blood concentrations of alemtuzumab and antiglobulin responses in patients with chronic lymphocytic leukemia following intravenous or subcutaneous routes of administration
    Geoff Hale
    Therapeutic Antibody Centre, Old Road, Headington, Oxford, OX3 7JT, United Kingdom
    Blood 104:948-55. 2004
    ..Subcutaneous alemtuzumab is more convenient and better tolerated but may be associated with some patients forming anti-alemtuzumab antibodies, particularly those patients who were previously untreated...
  61. ncbi request reprint High expression of bfl-1 contributes to the apoptosis resistant phenotype in B-cell chronic lymphocytic leukemia
    Alejo A Morales
    Microbiology and Tumor Biology Center, Karolinska Institutet, Stockholm, Sweden
    Int J Cancer 113:730-7. 2005
    ..05). We conclude that bfl-1 may be an important regulator of B-CLL apoptosis, which could contribute to disease progression and resistance to chemotherapy, and as such represent a future potential therapeutic target...
  62. ncbi request reprint Idiotype vaccination in multiple myeloma induced a reduction of circulating clonal tumor B cells
    Thomas Rasmussen
    Herlev Hospital, University of Copenhagen, Denmark
    Blood 101:4607-10. 2003
    ..Id vaccination may target clonal B cells, suggesting that this strategy might be conducive to achieving tumor control. The clinical significance of these findings remains to be established...
  63. ncbi request reprint Impact of epoetin-beta on survival of patients with lymphoproliferative malignancies: long-term follow up of a large randomized study
    Anders Osterborg
    Department of Oncology, Karolinska University Hospital, Stockholm, Sweden
    Br J Haematol 129:206-9. 2005
    ..76). This long-term follow up indicated that epoetin-beta has no significant effect on survival compared to placebo in anaemic patients with lymphoproliferative malignancies...
  64. ncbi request reprint No cardiac toxicity associated with alemtuzumab therapy for mycosis fungoides/Sézary syndrome
    Jeanette Lundin
    Blood 105:4148-9. 2005
  65. ncbi request reprint T-cell epitopes within the complementarity-determining and framework regions of the tumor-derived immunoglobulin heavy chain in multiple myeloma
    Lotta Hansson
    Department of Hematology, Karolinska Hospital, Stockholm, Sweden
    Blood 101:4930-6. 2003
    ..This study demonstrates that a large number of HLA-binding idiotypic peptides can be identified in patients with MM. Such peptides may spontaneously induce a type I MHC class I- as well as class II-restricted memory T-cell response...
  66. ncbi request reprint Fatal adenovirus infection during alemtuzumab (anti-CD52 monoclonal antibody) treatment of a patient with fludarabine-refractory B-cell chronic lymphocytic leukemia
    Nina Cavalli-Björkman
    Department of Hematology and Oncology, Karolinska Hospital, Stockholm, Sweden
    Med Oncol 19:277-80. 2002
    ....
  67. ncbi request reprint Leukemia-associated monoclonal and oligoclonal TCR-BV use in patients with B-cell chronic lymphocytic leukemia
    Mohammad Reza Rezvany
    Immune and Gene Therapy Laboratory, Cancer Center Karolinska, the Department of Oncology Radiumhemmet, Karolinska Hospital, Stockholm, Sweden
    Blood 101:1063-70. 2003
    ....
  68. ncbi request reprint Idiotype protein vaccination in combination with adjuvant cytokines in patients with multiple myeloma--evaluation of T-cell responses by different read-out systems
    Amir Osman Abdalla
    Immune and Gene Therapy Laboratory, Cancer Centre Karolinska, Stockholm, Sweden
    Haematologica 92:110-4. 2007
    ..053). Application of multiple read-out systems improved the characterization of the immune response...
  69. ncbi request reprint Clinical efficacy of zanolimumab (HuMax-CD4): two phase 2 studies in refractory cutaneous T-cell lymphoma
    Youn H Kim
    Multidisciplinary Cutaneous Lymphoma Program, Stanford Comprehensive Cancer Center, 875 Blake Wilbur Drive, Stanford, CA 94305, USA
    Blood 109:4655-62. 2007
    ..The treatment was well tolerated with no dose-related toxicity other than the targeted depletion of peripheral T cells. A pivotal study has been initiated based on these findings...
  70. ncbi request reprint Randomized, dose-finding study of darbepoetin alfa in anaemic patients with lymphoproliferative malignancies
    Michael Hedenus
    Medical Department, Sundsvall Hospital, Sundsvall, Sweden
    Br J Haematol 119:79-86. 2002
    ..Confirmative studies at doses of 2.25 and/or 4.5 microg/kg/week in this population are warranted...
  71. ncbi request reprint Immune response, depression and fatigue in relation to support intervention in mammary cancer patients
    Christina Lindemalm
    Immune and Gene Therapy Laboratory, Cancer Centre Karolinska, Karolinska University Hospital Solna, Stockholm, Sweden
    Support Care Cancer 16:57-65. 2008
    ..To study the effect of support intervention on immune function in breast cancer patients...
  72. ncbi request reprint A pilot study of alemtuzumab (anti-CD52 monoclonal antibody) therapy for patients with relapsed or chemotherapy-refractory peripheral T-cell lymphomas
    Gunilla Enblad
    Department of Oncology, Uppsala University Hospital, Uppsala, Sweden
    Blood 103:2920-4. 2004
    ..Further studies are warranted in younger patients and patients with less advanced disease...